CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project aims to clinically validate a new biomarker, CD32b, for B-cell malignancies to improve treatment outcomes. It also develops a novel therapy, BI-1206, targeting CD32b to enhance the effectiveness of existing treatments like rituximab. The project focuses on creating a diagnostic assay for clinical use.
The overall objective of the proposed project is the clinical validation of a novel biomarker for B-cell malignancies.
The presently most widely used anti-CD20 antibody treatment rituximab has considerably improved treatment options for patients with B-cell malignancies.
However, effectiveness is limited by resistance to rituximab and reduced response on repeated treatments.
Data indicates that tumor expression of CD32b is directly involved in the development of resistance to rituximab. CD32b ha…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
